Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Possis catheter approval

This article was originally published in The Gray Sheet

Executive Summary

Possis gains PMA supplement approval for AngioJet Spiroflex catheter for removal of blood clots from coronary arteries, the firm announces Jan. 30. Possis will launch Spiroflex through its 80-rep sales force into the roughly $150 million domestic coronary thrombectomy market. Spiroflex offers increased trackability and improved crossing in difficult anatomy compared with earlier versions, as well as quick 360-degree thrombus removal, Possis says. The Minneapolis-based firm expects approval of its SpiroflexVG for use in saphenous vein bypass grafts in the heart and larger native coronary vessels this year...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT024464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel